BMI and HbA1c are metabolic markers for pancreatic cancer: Matched case-control study using a UK primary care database
Open Access
- 4 October 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (10) , e0275369
Abstract
Weight loss, hyperglycaemia and diabetes are known features of pancreatic cancer. We quantified the timing and the amount of changes in body mass index (BMI) and glycated haemoglobin (HbA1c), and their association with pancreatic cancer from five years before diagnosis. A matched case-control study was undertaken within 590 primary care practices in England, United Kingdom. 8,777 patients diagnosed with pancreatic cancer (cases) between 1st January 2007 and 31st August 2020 were matched to 34,979 controls by age, gender and diabetes. Longitudinal trends in BMI and HbA1c were visualised. Odds ratios adjusted for demographic and lifestyle factors (aOR) and 95% confidence intervals (CI) were calculated with conditional logistic regression. Subgroup analyses were undertaken according to the diabetes status. Changes in BMI and HbA1c observed for cases on longitudinal plots started one and two years (respectively) before diagnosis. In the year before diagnosis, a 1 kg/m2 decrease in BMI between cases and controls was associated with aOR for pancreatic cancer of 1.05 (95% CI 1.05 to 1.06), and a 1 mmol/mol increase in HbA1c was associated with aOR of 1.06 (1.06 to 1.07). ORs remained statistically significant (p < 0.001) for 2 years before pancreatic cancer diagnosis for BMI and 3 years for HbA1c. Subgroup analysis revealed that the decrease in BMI was associated with a higher pancreatic cancer risk for people with diabetes than for people without (aORs 1.08, 1.06 to 1.09 versus 1.04, 1.03 to 1.05), but the increase in HbA1c was associated with a higher risk for people without diabetes than for people with diabetes (aORs 1.09, 1.07 to 1.11 versus 1.04, 1.03 to 1.04). The statistically significant changes in weight and glycaemic control started three years before pancreatic cancer diagnosis but varied according to the diabetes status. The information from this study could be used to detect pancreatic cancer earlier than is currently achieved. However, regular BMI and HbA1c measurements are required to facilitate future research and implementation in clinical practice.Keywords
This publication has 30 references indexed in Scilit:
- Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD)BMJ Open, 2013
- Principled missing data methods for researchersSpringerPlus, 2013
- New insights into pancreatic cancer-induced paraneoplastic diabetesNature Reviews Gastroenterology & Hepatology, 2013
- Identifying patients with suspected pancreatic cancer in primary care: derivation and validation of an algorithmBritish Journal of General Practice, 2012
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- Temporal Association of Changes in Fasting Blood Glucose and Body Mass Index With Diagnosis of Pancreatic CancerAmerican Journal of Gastroenterology, 2009
- New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancerThe Lancet Oncology, 2009
- Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes MellitusGastroenterology, 2008
- Pancreatic Cancer–Associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of CancerGastroenterology, 2008
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007